{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Chronic+Plaque-Type+Psoriasis&page=2", "query": { "condition": "Moderate to Severe Chronic Plaque-Type Psoriasis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Chronic+Plaque-Type+Psoriasis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T15:18:53.751Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01365455", "title": "Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "DRUG" }, { "name": "placebo to secukinumab 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2011-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365455" }, { "nct_id": "NCT02581345", "title": "Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Psoriasis" ], "interventions": [ { "name": "M923", "type": "BIOLOGICAL" }, { "name": "Humira", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Momenta Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2015-09", "completion_date": "2017-04-04", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 24, "location_summary": "Beverly Hills, California • Encino, California • La Mesa, California + 20 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02581345" }, { "nct_id": "NCT01309737", "title": "A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo/CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 960, "start_date": "2011-03", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-09-19", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309737" }, { "nct_id": "NCT00941031", "title": "AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "AIN457A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2009-07", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941031" }, { "nct_id": "NCT01555125", "title": "First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "DRUG" }, { "name": "secukinumab 300 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2012-05-08", "completion_date": "2016-10-24", "has_results": true, "last_update_posted_date": "2018-08-08", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555125" }, { "nct_id": "NCT02690701", "title": "Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2016-02-10", "completion_date": "2018-02-19", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02690701" }, { "nct_id": "NCT03504852", "title": "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 331, "start_date": "2018-06-25", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504852" }, { "nct_id": "NCT01186744", "title": "A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 666, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 50, "location_summary": "Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186744" }, { "nct_id": "NCT01107457", "title": "A Study in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2010-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 31, "location_summary": "Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01107457" }, { "nct_id": "NCT01412944", "title": "Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150mg", "type": "DRUG" }, { "name": "secukinumab 10mg/kg i.v. regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2011-12", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2015-03-18", "last_synced_at": "2026-06-10T15:18:53.751Z", "location_count": 6, "location_summary": "Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01412944" } ] }